177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy.

Saved in:

Bibliographic Details
Title:	¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy.
Authors:	John, Nikeith^1,2, Pathmanandavel, Sarennya¹, Crumbaker, Megan^2,3,4, Counter, William¹, Bao Ho¹, Yam, Andrew O.^2,3,4, Wilson, Peter⁵, Niman, Remy⁵, Ayers, Maria¹, Poole, Aron¹, Hickey, Adam¹, Agrawal, Shikha¹, Perkins, Gary¹, Kallinen, Annukka¹, Eslick, Enid¹, Stockler, Martin R.⁶, Joshua, Anthony M.^2,3,4, Nguyen, Andrew^1,2, Emmett, Louise^1,2,3 louise.emmett@svha.org.au
Source:	Journal of Nuclear Medicine. Mar2023, Vol. 64 Issue 3, p410-415. 6p.
Database:	Engineering Source

Be the first to leave a comment!